antobody-fused MeCP2 protein replacement (ArmaGen)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameantobody-fused MeCP2 protein replacement (ArmaGen)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionMethyl-CpG-binding protein 2 stimulants
TargetsMethyl-CpG-binding protein 2
Therapy Area/IndicationsRett Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArmagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArmagen Inc
Active IndicationsN/A
Inactive IndicationsRett Syndrome

Other Information

ATC CodeN/A
Related LinksN/A